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Role of nutrition in liver transplantation for end-stage chronic
liver disease
Felix Stickel, Daniel Inderbitzin, and Daniel Candinas
Patients with end-stage liver disease often reveal signiﬁcant protein-energy
malnutrition, which may deteriorate after listing for transplantation. Since
malnutrition aﬀects post-transplant survival, precise assessment must be an
integral part of pre- and post-surgical management. While there is wide agreement
that aggressive treatment of nutritional deﬁciencies is required, strong scientiﬁc
evidence supporting nutritional therapy is sparse. In practice, oral nutritional
supplements are preferred over parenteral nutrition, but enteral tube feedingmaybe
necessary tomaintain adequate calorie intake. Protein restriction should be avoided
and administration of branched-chain amino acids may help yield a suﬃcient
protein supply. Speciﬁc problems such as micronutrient deﬁciency, ﬂuid balance,
cholestasis, encephalopathy, and comorbid conditions need attention in order to
optimize patient outcome.
© 2008 International Life Sciences Institute
INTRODUCTION
Orthotopic liver transplantation (OLT) has greatly
improved the prognosis of patients with chronic liver
failure, and clinical features of declining liver function
largely normalize following successful organ replacement.
Among the most prevalent complications of chronic liver
failure is a marked impairment of the nutritional status
due to both primary and secondary malnutrition. The
degree of malnutrition has been a parameter of the old
version of the Child-Pugh index; however, the lack of
universally applicable diagnostic tools to precisely diag-
nosemalnutrition in clinical practice has left the diagnosis
based on clinical signs of encephalopathy and ascites as
well as the laboratory parameters serum bilirubin, serum
albumin, and prothrombin time (index).1 Interestingly,
the model for end-stage liver disease (MELD), initially
developed for prediction of survival of patients with com-
plications of portal hypertension scheduled for a trans-
jugular intrahepatic portosystemic shunt, is now widely
used for organ allocation in liver transplant programmes,
but it does not consider nutritional status at all.2 Possibly,
its failure to accurately predict survival in approximately
15–20%of potential transplant recipients relates to the fact
that malnutrition does not inﬂuence MELD ﬁgures.
No controversy currently exists regarding the impor-
tance of nutritional status as an important predictor of
post-transplant outcome and the beneﬁts of its therapeu-
tic improvement, although evidence from randomized
clinical trials is limited. The present review aims to sum-
marize the current evidence on nutritional aspects in liver
transplantation both in the pre- and post-transplant
setting in order to highlight the importance of suﬃcient
nutritional support as a valuable intervention to improve
patients’ overall prognosis and quality of life.
PREVALENCE AND SIGNIFICANCE OF MALNUTRITION
IN END-STAGE LIVER DISEASE
With the exception of patients with fulminant hepatic
failure, most candidates for OLT present with signiﬁcant
malnutrition, and nutritional deﬁciencies usually evolve
prior to clinical signs of hepatic insuﬃciency. Protein
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energy malnutrition (PEM), in particular, is frequently
encountered in patients with cirrhosis of nearly every
etiology.3 Even in stable cirrhotic patients, who are com-
monly referred to as having Child A cirrhosis, protein
depletion is prevalent in approximately 20% of patients.4
This ﬁgure rises sharply as liver insuﬃciency progresses,
and a majority of patients with Child C cirrhosis have
signiﬁcant nutritional deﬁciencies.5–8 PEM clinically pre-
sents with weakness, muscle wasting, weight loss, nausea,
and anorexia; its prevalence is similar in advanced alco-
holic liver disease and other causes of liver cirrhosis.7,9 In
alcoholic cirrhosis, PEM is closely associated with com-
plications of cirrhosis including infections, encephalopa-
thy, development of ascites, and variceal bleeding,10,11
as well as with reduced patient and graft survival after
OLT.12,13
Patients with end-stage liver disease are often deﬁ-
cient in various vitamins and other micronutrients.14
Cirrhotic alcoholics are especially susceptible to severe
vitamin depletion, particularly that of folate and
pyridoxal-5′-phosphate, the biologically active coenzyme
of vitamin B6,with both occurring in up to 70% of cases.15
Thiamine levels are also frequently decreased in patients
with alcoholic and hepatitis C-related cirrhosis, which
may elicit the Wernicke-Korsakoﬀ syndrome and Beri-
Beri cardiomyopathy.16 A typical feature of early and
advanced alcoholic liver disease is an increasingly severe
reduction of hepatic vitamin A stores, which sometimes
leads to infertility and night blindness.17 In vitamin
A-deﬁcient cirrhotics, its supplementation, even at rela-
tively moderate doses, may further aggravate liver injury
since high-dose vitamin A preparations may be hepato-
toxic due to polar retinoid metabolites that cause hepato-
cellular apoptosis and may promote ﬁbrogenesis.18,19 Zinc
deﬁciency is common in patients with decompensated
cirrhosis and likely relates to decreased absorption and a
diuretics-induced increase in its urinary excretion. Clini-
cally, zinc deﬁciency presents with alterations of smell
and taste, protein metabolism, and encephalopathy.
Regarding the latter, one study showed that zinc supple-
mentation resulted in lower ammonia levels following an
alanine challenge, and improvements of psychometric
tests, liver function, and Child-Pugh score,20 but another
study did not replicate these ﬁndings.21
Reduced nutritional status has been identiﬁed as
an independent predictor of poor prognosis in patients
with liver cirrhosis22,23 and an indicator of unfavorable
outcome after liver transplantation.24
CAUSES OF MALNUTRITION IN
END-STAGE LIVER DISEASE
The liver is the largest metabolic organ of the human
body and plays a prime role in the turnover of carbohy-
drates, lipids, proteins, vitamins, and trace minerals; it is
also an important part of the immune system. Literally all
functional properties of the liver are profoundly impaired
in end-stage liver disease (ESLD). Malnutrition in
patients with ESLD has numerous causes, some of which
relate to the underlying etiology of liver damage while
others are universal features of declining liver function
irrespective of the type of liver disease. Both primary and
secondary factors contribute to poor nutritional status
and must be accounted for in the management of these
patients. The most relevant causes of malnutrition in
patients with ESLD are as follows: 1) Dietary insuﬃ-
ciency: a) anorexia, nausea, vomiting; b) early satiety, taste
abnormalities, poor palatability of diets (protein and salt
restriction); c) reﬂux disease (ascites, abnormal gut motil-
ity): 2) Malabsorbtion: a) pancreatic insuﬃciency; b)
cholestasis (fat soluble vitamins); c) drug-related diar-
rhoea (lactulose, antibiotics, diuretics, cholestyramine): 3)
Metabolic disturbances: a) hypermetabolism during com-
plications (infections, haemorrhage, ascitic decompensa-
tion); b) protein catabolism (inﬂammation, impaired liver
synthesis); c) impairment of glucose homeostasis due to
hepatic insulin resistance (altered gluconeogenesis, low
glycogen stores, impaired glycogenolysis); d) increased
lipolysis, enhanced lipid oxidation; e) proinﬂammatory
cytokines (TNFa, interleukins, leptin): 4) Iatrogenic: a)
investigative procedure-related fasting periods; b) protein
restriction during periods of encephalopathy; c) large
volume paracentesis.
Notably, the majority of patients with ESLD have
no increased resting energy expenditure (REE). A recent
study found a normal energy balance in clinically
stable cirrhotic patients with malnutrition as assessed
by anthropometry.25 Seventy-four consecutive cirrhotic
patients and nine healthy controls were investigated
using indirect calorimetry adjusted according to the
patients’ physical activity. Thirty-two patients in the cir-
rhotic group were classiﬁed as severely malnourished, but
basal energy expenditure (BEE) was similar in all three
groups; the non-protein respiratory quotient was lower
in cirrhotics notwithstanding their nutritional status.
In addition, no diﬀerence in the estimated daily energy
expenditure and energy intake was observed among
groups.
A major reason for primary malnutrition in patients
prior to transplantation is reduced food consumption due
to anorexia.26 Low calorie intake may also be traced to
several other reasons including unpalatable diet compo-
sition due to salt and protein restriction,23 early satiety
because of ascites and portal gastropathy,27 and loss of
appetite due to upregulated mediators of inﬂammation
and mediators of appetite such as tumor necrosis factor-
alpha and leptin.28,29 In addition, in up to 45% of cirrhot-
ics coexisting infection withHelicobacter pylorimay cause
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dyspepsia and a decreased desire for food.30 Signiﬁcant
malnutrition may be the result of maldigestion related to
pancreatic or biliary abnormalities such as exocrine pan-
creatic insuﬃciency or primary biliary liver disorders,
while malabsorbtion can result from applied medications
such as lactulose or antibiotics causing diarrhea.31
Impaired glucose tolerance due to insulin resistance
and established diabetes has an important impact on
nutritional status in many cirrhotic patients. Due to
impaired glyconeogenesis, the cirrhotic liver fails to store
suﬃcient amounts of glycogen; this results in glyconeo-
genesis from protein catabolism and lipid oxidation.32
Therefore, periods of fasting should be avoided in cir-
rhotic patients, and frequent meals should be imple-
mented to prevent protein catabolism. In fact, late
evening meals and nocturnal glucose supplementation
has been shown to improve nitrogen balance in cirrhotic
patients.33,34
NUTRITIONAL ASSESSMENT
For assessing nutritional status in patients with ESLD
on the transplant waiting list no accepted diagnostic
“gold standard” exists; in fact, several surrogate markers
of an individual’s nutritional status are usually necessary
to obtain valid data on the severity and pattern of
malnutrition.
One useful, easily applicable, and validated approach
is subjective global assessment (SGA). This method inte-
grates a detailed medical and dietary history, body weight
and height, coexisting medical conditions, and physical
activity to rate patients either “well-nourished”, “moder-
ately malnourished”, or “severely malnourished”. The
dietary history is ideally recorded by an experienced
dietician. SGA is highly speciﬁc (96%) for the detection of
malnutrition in liver transplant candidates,35 but it lacks
sensitivity in patients with severe alcoholic liver disease.36
Easily applicable techniques include anthropometric
measurements such as body mass index (BMI), triceps
skin fold thickness, and mid-arm muscle circumference
(MAMC). Unfortunately, most of the easily applicable
methods are confounded by signiﬁcant ﬂuid retention in
cirrhotics with ascites and peripheral edema. Reference
values for triceps skin fold thickness and MAMC as
simple bedside tests for nutritional assessment are given
in Table 1. BMI in particular has been criticized for yield-
ing falsely high values, but correction by subtracting esti-
mated amounts of ascites and other ﬂuid collections may
compensate for this disadvantage to some extent.8
Biochemical markers of malnutrition include serum
albumin concentration and measurements of 24-hour
creatinine excretion related to a reference population.
While the former obviously varies signiﬁcantly due to
hepatic function, the latter has been suggested as an indi-
rect measure of body muscle mass, as 1 g of excreted
creatinine equals 18.5 kg of muscle mass.37 A more
sophisticated, but less widely available, examination tool
for assessing body composition is bioelectric impedance
analysis (BIA).BIA is a precise and noninvasive technique
that measures lean body mass and fat stores; however,
it also becomes inaccurate when patients retain ﬂuid.
Another noninvasive method is dual x-ray absorptiom-
etry (DEXA),which provides exact measurements of total
body composition.Again, its accuracy declines in patients
with ascites and edema. These shortcomings may be
bypassed with more precise approaches such as in vivo-
neutron activation analysis and isotope dilution tech-
niques,38 but since application of these methods is
time-consuming and costly, their use is restricted to
research purposes.
Considering these feasibility issues, the European
Society for Parenteral and Enteral Nutrition (ESPEN) has
published updated guidelines on enteral nutrition in liver
transplant candidates.39 The current guidelines recom-
mend simple bedside methods such as SGA and/or
anthropometry parameters to identify patients at risk for
poor nutritional status and BIA to quantify undernutri-
tion despite the limitations of all techniques in patients
with ascitic decompensation.39 According to the ESPEN
expert panel, other composite nutrition scores provide no
additional prognostic information.
NUTRITIONAL INTERVENTION – THERAPEUTIC AIMS
Patients with ESLD on the transplant waiting list
frequently display a gradual decline of their nutritional
Table 1 Bedside tests for simple assessment of malnutrition.
Anthropometric test Normal Moderate Severe
Triceps skin fold thickness
Men 7.5–12.5 mm 4–6 mm <4 mm
Women 10–16.5 mm 5–8 mm <5 mm
Mid-arm muscle circumference
Men 23.0–25.5 cm 18–20 cm <18 cm
Women 21–23 cm 6–18.5 cm <16 cm
Adapted from Selberg et al.22 (Hepatology 1997;25:652–657).
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condition. As a result, the major goals of pre-transplant
nutritional therapy are to prevent further nutrient and
protein depletion and to correct macro- and micronutri-
ent deﬁciencies. Nutritional support should include the
administration of suﬃcient amounts of calories, proteins,
vitamins,minerals, and trace elements without exacerbat-
ing liver disease-related complications such as portosys-
temic encephalopathy, ﬂuid retention, and electrolyte
imbalances. Determining the extent of nutritional
supplementation requires calculation of the individual’s
energy needs; this can be done by calculating BEE using
the Harris Benedict equation while considering the ideal
body weight rather than the patient’s actual weight
(Table 2). As a rule of thumb, the total calories should be
a minimum of 1.2 times the BEE, equalling 35–40 kcal/kg
body weight daily, and 60–70% should derive from car-
bohydrates.40
Portosystemic encephalopathy is frequent in OLT
candidates with ESLD, and many clinicians implement
protein restriction to treat it. However, this should be
avoided as a routine measure since it aggravates PEM.
Instead, encephalopathy should be treated aggressively
with standard therapy using lactulose and treatment of
precipitating causes such as infections and gastrointesti-
nal hemorrhage. Usually, standard amino acid formulas
are well tolerated and should provide at least 1g
protein/kg body weight per day, which can be increased
to 1.2–2.0 g/kg daily when tolerated.23,40,41 The usefulness
of branched-chain amino acids (BCAA) has not been
speciﬁcally investigated in patients with ESLD on the
transplant waiting list, but it can be assumed that the
supportive evidence from two recent randomized trials
suggesting that long-term (<12 months) nutritional
supplementation with oral BCAA is beneﬁcial in slowing
the progression of hepatic failure and prolonging event-
free survival in liver cirrhotics also applies for OLT
candidates.42,43 In practice, whole-protein formulas are
generally recommended, and BCAA-enriched formulas
should be used in patients who develop encephalopathy
during refeeding.
Osteopenia and osteoporosis is frequent in patients
with ESLD; therefore, calcium and vitamin D supplemen-
tation is recommended for all patients on the waiting list.
In those with established osteoporosis or a history of frac-
tures, calcium and vitamin D supplementation should be
combined with bisphosphonates.23
ROUTE OF NUTRITIONAL SUPPORT
Nutritional supplements should, ideally, be administered
enterally, either by oral supplements or, if active eating is
hampered, through a gastric or jejunal tube since patients
appear to beneﬁt from topical nutritional factors in the
gut. Another argument favoring oral nutrition is the
lower rate of infections that may occur with central
venous catheters. Concerns such as precipitating variceal
hemorrhage while inserting the feeding tube have not
been conﬁrmed in clinical trials.44 However, reports of
complications related to malpositioned feeding tubes
continue to surface; most are due to inadvertent disloca-
tion in the respiratory tract causing aspiration, especially
when the tube is placed in the esophagus. Other
complications observed occasionally with nasogastric/
nasoduodenal tubes include epistaxis, sinusitis, tube
removal or retraction, tube clogging, and tube-feeding-
associated diarrhea.45,46 However, complications related
to malpositioned feeding tubes are usually preventable
if correct placement is safely achieved and regularly
monitored.
Total parenteral nutrition (TPN) should be restricted
to patients who are unable to eat or those for whom
enteral feeding is contraindicated. In cases of severe gas-
trointestinal dysfunction, such as esophageal bleeding or
intestinal obstruction, TPN remains an option to ensure
adequate caloric intake. However, TPN is associated with
higher risks of infection and electrolyte imbalance, it is
more expensive, and since evidence supporting its use in
ESLD stems from studies focused on the treatment of
severe alcoholic liver disease, it may not apply to patients
waiting for liver transplantation.9,23
NUTRITIONAL THERAPY BEFORE LIVER
TRANSPLANTATION
Until now, only two prospective controlled trials investi-
gated the eﬀect of pre-transplant nutritional therapy on
the outcome of patients undergoing OLT. Chin et al.47
prospectively included 19 children with ESLD, with a
median age of 1.25 years, to compare a high-energy,
isoenergetic and isonitrogenous BCAA-enriched semi-
elemental formulation with a matched standard semi-
elemental formation. Only 12 of 19 patients completed
the study before OLT, and only 10 of 19 completed a full
crossover study. Both regimens improved weight and
height, whereas the BCAA formula resulted in signiﬁ-
cantly more pronounced improvements of total body
potassium,mid-upper-arm circumference, and subscapu-
Table 2 Harris-Benedict equation.
Gender Resting energy expenditure
Female 66.5 + (9.56 ¥ body weight [kilogram]) +
(1.85 ¥ height [centimetres]) –
4.676 ¥ age (years)
Male 66.5 + (13.75 ¥ body weight [kilogram]) +
(5.0 ¥ height [centimetres]) –
6.75 ¥ age (years)
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lar skin fold thickness in comparison to the standard
formulation. Also, signiﬁcantly fewer albumin infusions
were required during the BCAA supplement.The authors
concluded that BCAA-enriched formulas seem to have
advantages over standard semi-elemental formulas for
improving nutritional status in children with ESLD listed
for OLT.Obviously, the low number of patients limits the
signiﬁcance of these results. A slightly larger prospective
randomized controlled trial from the United Kingdom
examined the eﬀect of pre-transplant nutritional supple-
mentation on the outcome of 82 adult patients (42 with
active enteral nutritional therapy in addition to regular
diet; 40 control patients without additional nutrition)
undergoing liver transplantation.48 Nutritional supple-
mentation improved mid-arm circumference, mid-arm
muscle circumference, and grip strength. However,
supplementation did not aﬀect survival, although there
were more deaths in the control group than there were in
the supplemented group (nine versus ﬁve, p = 0.075).
Although the importance of nutritional therapy for
patients with ESLD listed for OLT is generally accepted,49
clear scientiﬁc evidence supporting this view is scarce and
no study has demonstrated that preoperative nutritional
therapy of whatever kind improves the outcome of liver
transplantation.
NUTRITIONAL THERAPY AFTER LIVER
TRANSPLANTATION
Although most nutritional deﬁciencies and metabolic
disturbances prevalent in patients with ESLD rapidly
improve following successful OLT, preoperative malnu-
trition, surgical stress, post-interventional complica-
tions, postoperative protein catabolism, and fasting
periods suggest the need for early nutritional support
after OLT. Expert guidelines recommend that 1.5–
2.0 g protein/kg body weight should be administered
daily to liver transplant recipients during the immediate
post-transplant period; this is to compensate for the
signiﬁcant loss of nitrogen caused by the excretion of
large amounts of urinary nitrogen.23,40 Ideally, nutrition
should be given either orally or enterally via a nasogas-
tric tube since this is associated with lower postoperative
rates of infection50 and fewer metabolic disturbances51
than TPN.
So far, only a few clinical studies have elucidated the
role of postoperative nutritional therapy in patients who
received a liver transplant. Reilly et al.52 investigated a
total of 28 patients for the eﬀects of two TPN regimens,
either with standard amino acids or BCAA immediately
after OLT, in comparison with the eﬀects of a glucose
infusion administered for 7 days. Both TPN treatment
regimens were equally eﬀective and performed better
than the glucose infusion, as reﬂected by an improved
nitrogen balance and a shorter duration of ventilation
therapy and stay on the intensive care unit. This small
study provided supportive evidence for nutritional
therapy in general but clearly neglected possible beneﬁts
from oral or enteral feeding. The latter issue was
addressed in another study that randomized 50 trans-
plant patients to receive either an enteral formula via
nasointestinal feeding tubes or maintenance intravenous
ﬂuid until oral diets were initiated.51 Only 31 patients
completed the trial for evaluation. The tube-fed patients
(N = 14) showed signiﬁcantly higher total nutrient
intakes, a better nitrogen balance, and developed
infections less frequently. Early post-transplant tube
feeding did not inﬂuence hospitalization costs, hours
on the ventilator, lengths of stay in the intensive care
unit and hospital, or rejection during the ﬁrst 21 days
post-transplant.
Only one study directly compared early parenteral
with enteral nutrition in the immediate post-operative
phase after OLT.53 Patients were randomly assigned 28
hypoalbuminemic cirrhotic patients immediately after
liver transplantation to receive either no nutritional
support (N = 10), TPN providing 35 kcal/kg/day with
standard amino acids at 1.5 g/kg/day (N = 8), or isoca-
loric isonitrogenous TPN with added BCAA (N = 10) for
7 days post-transplant. Both TPN groups showed a better
nitrogen balance, and a (non-signiﬁcant) shorter time
on ventilation and faster discharge from the intensive
care unit.
To conclude, early post-transplant nutritional
therapy seems to improve a number of surrogates of
nutritional status in recipients, but clear evidence for an
improvement of post-transplant outcome is lacking.
An innovative approach was chosen in a recent pilot
study fromNewZealand,which investigated the therapeu-
tic beneﬁt from pre- and post-operative immuno-
nutrition in liver transplant patients.54 The underlying
rationale for using immuno-nutrition is based on the
observation that post-operative nutritional supplementa-
tion with a formula consisting of arginine, ﬁsh oil,
and nucleotides proved to be beneﬁcial for reducing
post-operative infectious complications in patients under-
going gastrointestinal surgery; this is possibly due to
down-regulatory eﬀects on inﬂammatory responses and
amelioration of postoperative immunosuppression rather
than due to eﬀects on nutrition per se.55 Fifteen consecu-
tive patients received a commercial immuno-nutritional
preparation (0.6 L/d) for a median of 54 days pre- and
post-transplant in a non-randomized fashion; outcome
was compared to that of 17 patientswho received standard
nutritional intervention. Immuno-nutritional interven-
tionwas tolerated verywell and resulted innon-signiﬁcant
improvements of pre-operative nutritional status,
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accelerated recovery after transplantation, and reduced
postoperative infectious complications. Although the
study was small and uncontrolled, the favorable results
seem to justify a subsequent controlled trial.
Rayes et al.56 carried out a prospective randomized
double-blind trial in 66 liver transplant recipients who
received enteral nutrition in the immediate pre- and
post-operative periods. Outcome was compared between
a group receiving a commercial composition of four
strains of lactic acid bacteria and four ﬁbers and another
group receiving the ﬁbers only. Treatment started the
day before surgery and continued for 14 days. The inci-
dence of post-operative bacterial infections was 48% in
the group receiving ﬁbers only and 3% in those receiv-
ing LAB and ﬁbers (P < 0.05). In addition, the duration
of antibiotic therapy was signiﬁcantly shorter in the
latter group. In both groups, only mild or moderate
infections occurred. Although this study did not choose
nutritional endpoints to assess therapeutic eﬀects, the
results suggest a possible beneﬁt from certain “neutri-
ceutic” on important determinants of post-operative
outcome.
ESPEN has recently issued a detailed statement on
guidelines regarding the management of patients with
ESLD, liver transplant candidates, and subjects needing
major surgical interventions.39 Herein, recommendations
regarding patients awaiting liver transplantation largely
overlap with those issued for patients with liver cirrhosis.
Details of these recommendations are summarized in
Table 3.
CONCLUSIONS
Nutritional aspects are important both for patients await-
ing liver transplantation and for those who live on with a
liver graft.While pre-transplant patients and those in the
immediate post-transplant period usually require correc-
tion of numerous nutritional deﬁciencies to improve
their overall condition, post-transplant liver patients have
to be followed up to ensure they do not develop over
nutrition. Both settings require an interdisciplinary
approach that integrates the expertise of physicians, sur-
geons, nutritionists, and nursing staﬀ who are well-aware
of these issues. Only with joint eﬀorts can nutritional
imbalances be overcome to optimize the outcome of
patients in liver transplant programs.
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